Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814147 | 1.00 | ADRB2 (0.50) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL319930 | 1.00 | ADRB2 (0.50) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| Hydrochloric Acid SCHEMBL4233791 | 0.98 | ADRB2 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| Hydrochloric Acid SCHEMBL1001689 | 0.98 | ADRB2 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| Hydrochloric Acid SCHEMBL2161107 | 0.98 | ADRB2 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL29225796 | 0.94 | KIF11 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL29225795 | 0.94 | KIF11 (0.48) | ADRB2CYP2A6ALDH1A1CYP19A1LOXL2 | |
| SCHEMBL7778714 | 0.85 | KIF11 (0.59) | ADRB2CYP2A6ALDH1A1CYP19A1PDE2A | |
| SCHEMBL7799578 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1CYP19A1LOXL2CA12 | |
| SCHEMBL13557870 | 0.80 | CYP2A6 (0.52) | CYP2A6ALDH1A1CYP19A1LOXL2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321055-B2 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | claimed |
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1749816-A1 | Production method of optically active diphenylalanine compounds | Ajinomoto Co., Ltd. (JP) | 2007-02-07 | — | — | EP | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4514788-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034268-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5932567-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| EP-0809651-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0773955-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996024609-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1995035309-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | ADRB2 213/4885CYP2A6 4216/4885ALDH1A1 2682/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ADRB2 4868/4885CYP2A6 4274/4885ALDH1A1 4101/4885 |
| US-20070032658-A1 | Production method of optically active dephenylalanine compounds | TYR, PAH, DDC | ADRB2 1338/4885CYP2A6 1178/4885ALDH1A1 299/4885 |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | ADRB2 23/4885CYP2A6 1320/4885ALDH1A1 3600/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | ADRB2 45/4885CYP2A6 400/4885ALDH1A1 973/4885 |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | ADRB2 23/4885CYP2A6 1320/4885ALDH1A1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.